A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers

Shoumin Zhu, Zheng Chen, Lihong Wang, Dunfa Peng, Abbes Belkhiri, Albert Lockhart, Wael El-Rifai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: We aimed to investigate the therapeutic efficacy of single agent and the combination of quinacrine and suberoyla-nilide hydroxamic acid (SAHA) in wt- and mut-p53 upper gastrointestinal cancer (UGC) cell models. Experimental Design: ATP-Glo, clonogenic cell survival, Annexin V, comet, DNA double-strand breaks (DSBs), qPCR, and Western blot analysis assays were utilized. Results: Using clonogenic cell survival, ATP-Glo cell viability, Annexin V, and sub-G0 population analysis, we demonstrated that a combination of quinacrine and SAHA significantly decreased colony formation and increased cancer cell death (range, 4–20 fold) in six UGC cell models, as compared with single-agent treatments, irrespective of the p53 status (P < 0.01). The combination of quinacrine and SAHA induced high levels of DSB DNA damage (>20-fold, P < 0.01). Western blot analysis showed activation of caspases-3, 9, and g-H2AX in all cell models. Of note, although quinacrine treatment induced expression of wt-p53 protein, the combination of quinacrine and SAHA substantially decreased the levels of both wt-P53 and mut-P53. Furthermore, cell models that were resistant to cisplatin (CDDP) or gefitinib treatments were sensitive to this combination. Tumor xenograft data confirmed that a combination of quinacrine and SAHA is more effective than a single-agent treatment in abrogating tumor growth in vivo (P < 0.01). Conclusions: Our novel findings show that the combination of quinacrine and SAHA promotes DNA damage and is effective in inducing cancer cell death, irrespective of p53 status and resistance to CDDP or gefitinib in UGC models.

Original languageEnglish (US)
Pages (from-to)1905-1916
Number of pages12
JournalClinical Cancer Research
Volume24
Issue number8
DOIs
StatePublished - Apr 15 2018

Fingerprint

Hydroxamic Acids
Quinacrine
Gastrointestinal Neoplasms
Cell Death
Neoplasms
Cell Survival
Annexin A5
Adenosine Triphosphate
Western Blotting
Activation Analysis
Double-Stranded DNA Breaks
Caspase 9
Heterografts
Caspase 3
Cisplatin
DNA Damage
Research Design
Growth
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers. / Zhu, Shoumin; Chen, Zheng; Wang, Lihong; Peng, Dunfa; Belkhiri, Abbes; Lockhart, Albert; El-Rifai, Wael.

In: Clinical Cancer Research, Vol. 24, No. 8, 15.04.2018, p. 1905-1916.

Research output: Contribution to journalArticle

@article{e2b39472e9414af3b96ee54d8c078e9e,
title = "A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers",
abstract = "Purpose: We aimed to investigate the therapeutic efficacy of single agent and the combination of quinacrine and suberoyla-nilide hydroxamic acid (SAHA) in wt- and mut-p53 upper gastrointestinal cancer (UGC) cell models. Experimental Design: ATP-Glo, clonogenic cell survival, Annexin V, comet, DNA double-strand breaks (DSBs), qPCR, and Western blot analysis assays were utilized. Results: Using clonogenic cell survival, ATP-Glo cell viability, Annexin V, and sub-G0 population analysis, we demonstrated that a combination of quinacrine and SAHA significantly decreased colony formation and increased cancer cell death (range, 4–20 fold) in six UGC cell models, as compared with single-agent treatments, irrespective of the p53 status (P < 0.01). The combination of quinacrine and SAHA induced high levels of DSB DNA damage (>20-fold, P < 0.01). Western blot analysis showed activation of caspases-3, 9, and g-H2AX in all cell models. Of note, although quinacrine treatment induced expression of wt-p53 protein, the combination of quinacrine and SAHA substantially decreased the levels of both wt-P53 and mut-P53. Furthermore, cell models that were resistant to cisplatin (CDDP) or gefitinib treatments were sensitive to this combination. Tumor xenograft data confirmed that a combination of quinacrine and SAHA is more effective than a single-agent treatment in abrogating tumor growth in vivo (P < 0.01). Conclusions: Our novel findings show that the combination of quinacrine and SAHA promotes DNA damage and is effective in inducing cancer cell death, irrespective of p53 status and resistance to CDDP or gefitinib in UGC models.",
author = "Shoumin Zhu and Zheng Chen and Lihong Wang and Dunfa Peng and Abbes Belkhiri and Albert Lockhart and Wael El-Rifai",
year = "2018",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-17-1716",
language = "English (US)",
volume = "24",
pages = "1905--1916",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers

AU - Zhu, Shoumin

AU - Chen, Zheng

AU - Wang, Lihong

AU - Peng, Dunfa

AU - Belkhiri, Abbes

AU - Lockhart, Albert

AU - El-Rifai, Wael

PY - 2018/4/15

Y1 - 2018/4/15

N2 - Purpose: We aimed to investigate the therapeutic efficacy of single agent and the combination of quinacrine and suberoyla-nilide hydroxamic acid (SAHA) in wt- and mut-p53 upper gastrointestinal cancer (UGC) cell models. Experimental Design: ATP-Glo, clonogenic cell survival, Annexin V, comet, DNA double-strand breaks (DSBs), qPCR, and Western blot analysis assays were utilized. Results: Using clonogenic cell survival, ATP-Glo cell viability, Annexin V, and sub-G0 population analysis, we demonstrated that a combination of quinacrine and SAHA significantly decreased colony formation and increased cancer cell death (range, 4–20 fold) in six UGC cell models, as compared with single-agent treatments, irrespective of the p53 status (P < 0.01). The combination of quinacrine and SAHA induced high levels of DSB DNA damage (>20-fold, P < 0.01). Western blot analysis showed activation of caspases-3, 9, and g-H2AX in all cell models. Of note, although quinacrine treatment induced expression of wt-p53 protein, the combination of quinacrine and SAHA substantially decreased the levels of both wt-P53 and mut-P53. Furthermore, cell models that were resistant to cisplatin (CDDP) or gefitinib treatments were sensitive to this combination. Tumor xenograft data confirmed that a combination of quinacrine and SAHA is more effective than a single-agent treatment in abrogating tumor growth in vivo (P < 0.01). Conclusions: Our novel findings show that the combination of quinacrine and SAHA promotes DNA damage and is effective in inducing cancer cell death, irrespective of p53 status and resistance to CDDP or gefitinib in UGC models.

AB - Purpose: We aimed to investigate the therapeutic efficacy of single agent and the combination of quinacrine and suberoyla-nilide hydroxamic acid (SAHA) in wt- and mut-p53 upper gastrointestinal cancer (UGC) cell models. Experimental Design: ATP-Glo, clonogenic cell survival, Annexin V, comet, DNA double-strand breaks (DSBs), qPCR, and Western blot analysis assays were utilized. Results: Using clonogenic cell survival, ATP-Glo cell viability, Annexin V, and sub-G0 population analysis, we demonstrated that a combination of quinacrine and SAHA significantly decreased colony formation and increased cancer cell death (range, 4–20 fold) in six UGC cell models, as compared with single-agent treatments, irrespective of the p53 status (P < 0.01). The combination of quinacrine and SAHA induced high levels of DSB DNA damage (>20-fold, P < 0.01). Western blot analysis showed activation of caspases-3, 9, and g-H2AX in all cell models. Of note, although quinacrine treatment induced expression of wt-p53 protein, the combination of quinacrine and SAHA substantially decreased the levels of both wt-P53 and mut-P53. Furthermore, cell models that were resistant to cisplatin (CDDP) or gefitinib treatments were sensitive to this combination. Tumor xenograft data confirmed that a combination of quinacrine and SAHA is more effective than a single-agent treatment in abrogating tumor growth in vivo (P < 0.01). Conclusions: Our novel findings show that the combination of quinacrine and SAHA promotes DNA damage and is effective in inducing cancer cell death, irrespective of p53 status and resistance to CDDP or gefitinib in UGC models.

UR - http://www.scopus.com/inward/record.url?scp=85047866235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047866235&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-1716

DO - 10.1158/1078-0432.CCR-17-1716

M3 - Article

VL - 24

SP - 1905

EP - 1916

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -